+ Follow ROBERT COLEMAN Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 246270
[Title] => Breast cancer drug boosts survival
[Summary] => At least 1,500 lives could be saved every year if a drug used to treat terminal breast cancer cases is given early in the disease.
The Breast Cancer International Research Group (BCIRG) said docetaxel (distributed by Aventis Pharma Inc.) significantly improved the survival rate of women with early-stage breast cancer and reduced their risk of a relapse compared with a standard treatment. This implies that docetaxel is a potential life-saver and should not only be used in terminally ill patients to buy extra time.
[DatePublished] => 2004-04-15 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
ROBERT COLEMAN
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 246270
[Title] => Breast cancer drug boosts survival
[Summary] => At least 1,500 lives could be saved every year if a drug used to treat terminal breast cancer cases is given early in the disease.
The Breast Cancer International Research Group (BCIRG) said docetaxel (distributed by Aventis Pharma Inc.) significantly improved the survival rate of women with early-stage breast cancer and reduced their risk of a relapse compared with a standard treatment. This implies that docetaxel is a potential life-saver and should not only be used in terminally ill patients to buy extra time.
[DatePublished] => 2004-04-15 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest